Utility of a Rapid, 6-Color, Randomly-Accessible, Real-Time PCR Instruments
Current PCR imaging systems generally limit testing to one, slow PCR protocol at a time. Therefore, the time frame to complete independent tests requires multiple runs over several hours or even days. Today, there is great demand for the development and design of next gen. PCR-based diagnostics for the rapid analysis of patient samples and simultaneous detection of multiple diverse markers. The time-critical clinical results include HLA matching / disease testing for organ transplantation, PCR-based diagnostic tests, antibiotic resistance testing / bacterial identification, co-infections such; HIV, tuberculosis, disease and toxin testing to determine the actual cause of symptoms, and forensics identification to name a few.
- Find out why intelligent engineering and rapid heat transfer are the keys to success
- Learn the value of a random access instrument when running multiple diagnostics test
- Learn how a real-time PCR imaging system is critical to target fields
- Learn about the selection of optimal PCR reagents for rapid PCR instrumentation
Business Development Manager, KMC Systems
Walter Gilde has more than 30 years of experience in the Life Science and In-Vitro Diagnostic industries. Prior to joining KMC Systems in 1996, he held sales and marketing management positions at leading and start-up diagnostic companies. He holds a bachelor’s degree in biology and medical technology from Northern Illinois University and The University of Health Sciences/Chicago Medical School. Walter worked in close partnership with Streck, Inc. to ensure the successul collaboration of the rapid, 6-color, randomly accessible, real-time PCR instrument project that will be discussed in this webiner.
Matthew R. Kreifels, PSM
R&D Manager – Molecular Technology, R&D
Matthew Kreifels is the Molecular Technology Manager for Streck. He has been employed with Streck, Inc. for 14 years and has held various roles in instrument and manufacturing equipment development. For the last four years, he has worked with internal and external teams to develop and commercialize a rapid molecular thermal cycling platform. The first instrument, a rapid conventional thermal cycler, and a patented plastic PCR tube consumable were released in 2012. Currently his team is developing a rapid 20-minute real-time thermal cycling platform. The application fields for the molecular platform include forensics, gram-negative resistance gene detection, tissue typing and related research. Matthew received a dual master’s degree in business and bio-science management in 2012 from Creighton University, Omaha, NE.
Scott Whitney, PhD.
Engineering, R&D Product Engineer, R&D
Scott Whitney, PhD, is a hardware designer, software developer, and relentless optimizer. He currently works at Streck as an R&D Product Engineer for the Philisa PCR and ESR-Auto Plus product lines. Scott has 14 years of experience with rapid detection, antibiotic resistance, and modeling of infectious agents such as Bacillus anthracis, Staphylococcus aureus, Mycobacterium smegmatis, Mycobacterium tuberculosis, and Clostridium Difficile. He is the author of numerous PCR papers on efficiency, error frequency, extension rates, gene synthesis, GC-rich templates, and instrument design. One of Scott’s instruments was described by Pete Moore in a technology feature in Nature regarding advances in PCR.
Chris Connelly, PhD.
R&D Scientist- Molecular Technology
Dr. Christopher M. Connelly is a Research and Development Scientist at Streck in the Molecular Technology Division. Dr. Connelly received his PhD in Biochemistry and Molecular Biology from the University of Nebraska Medical Center in 2010. He joined the research division at Streck in 2010. His areas of expertise involves protein biochemistry with a cancer research focus and the design and development of diagnostics relating to the genetic identification of antibiotic resistance in Gram-negative organisms. His current research explores development of rapid PCR-based diagnostic tests that can be used by clinical laboratories to detect resistance genes in clinical isolates, for HLA phenotyping, forensic identification, and other related research areas. Dr. Connelly has prior experience in technology transfer, FDA regulatory compliance, clinical trial study design, quality control/manufacturing, and management.